Table 1 Baseline demographics (n = 38).

From: Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings

Median age (years) (range)

48 (23–68)

Sex

n (%)

       Male

20 (52.6)

       Female

18 (47.4)

Comorbidities (overlapping)

14 (36.8)

       HTN

8 (21.0)

       DM

6 (15.8)

       Hypothyroidism

2 (5.3)

       CAD

2 (5.3)

       Rheumatic Heart Disease

2 (5.3)

       COPD

1 (2.6)

      Smoker n (%)

4 (10.5)

Previous lines of therapy

 1

5 (13.2)

 2

17 (44.7)

 3

9 (23.7)

 >4

7 (18.4)

Crizotinib

32 (84.2)

 >1 TKI

22 (57.9)

 2nd Gen TKI

29 (76.3)

ECOG PS

 1

30 (78.9)

 2

5 (13.1)

 >2

3 (7.9)

Site of Mets (Overlapping)

       Brain

21 (55.3)

       Bone

20 (52.6)

       Nodal

19 (50.0)

       Liver

15 (39.5)

       Lung

14 (36.8)

       Pleural effusion

14 (36.8)

       Pleural nodules

8 (21.1)

       Adrenal

4 (10.5)

       Others (Abdominal wall, muscle, breast)

3 (7.9)

  1. HTN hypertension, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, CAD Coronary artery disease, TKI Tyrosine kinase inhibitor, ECOG-PS Eastern Co-operative Oncology Group- Performance status.
Back to article page